FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211551408> ?p ?o ?g. }

• W3211551408 endingPage "336" @default.
• W3211551408 startingPage "336" @default.
• W3211551408 abstract "Abstract INTRODUCTION Immunocompromised patients have been excluded from initial trials evaluating SARS-CoV-2 mRNA vaccines and there is a critical need to warrant vaccine efficacy in hematopoietic stem cell transplant (HSCT) recipients. In this study, we evaluated antibody responses to 2 doses mRNA SARS-CoV-2 vaccine in allogeneic HSCT recipients. METHODS We retrospectively enrolled successive hematopoietic cell transplant recipients across France who completed the 2-dose SARS-CoV-2 mRNA vaccine (BNT162b2 or mRNA-1273) between January 1 st and July 15 th 2021. All included patients had an available semi-quantitative antispike serologic testing after the second dose (from Roche, DiaSorin, Abbott or Siemens). We excluded patients with a prior COVID-19 confirmed by serology or PCR. For detectable antibody, we calculated the binding antibody units per milliliter (BAU/mL) according to the WHO International Standard by applying conversion factors given by the manufacturers (Kristiansen et al. , The Lancet 2021). Antibody response was categorized as weak or good with a threshold of 264 BAU/mL which has been associated to an estimate of 80% of mRNA vaccine-induced protection against symptomatic COVID-19 in immunocompetent patients (Feng S. et al., medRxiv 2021). We built a multivariate logistic regression model to assess factors independently associated with the absence of antibody response after the second dose of mRNA vaccination. RESULTS Overall, 620 allogeneic HSCT recipients from 12 hospitals across France were included in the analysis (60% male with a median age of 59 years old [IQR 47-66]), most with a myeloid (69%) or lymphoid (26%) malignancies. Donors were matched unrelated for 51%, HLA-identical sibling for 31% and haplo-identical for 18%. Thirty-one percent of HSCT recipients underwent a myeloablative conditioning, while 69% received a reduced intensity conditioning. The two doses of vaccines were given one month apart and the median time between transplantation and the initiation of vaccination was 29 months [IQR 14-58]. At a median of 33 [IQR 27-50] days after dose 2, an antibody response was detectable in 496 patients (80% [95CI: 77 to 83%]). Median [IQR] antibody levels was 243 BAU/mL [29.4-1391]. We classified detectable antibody responses as weak in 189 patients (30% [95CI 27 to 34%]) and as good in 306 (49% [95CI: 45 to 53%]). In the multivariate analysis including 533 patients (420 with detectable antibodies), factors associated with the absence of humoral responses were a time-interval from HSCT &lt; 12 months (ajusted Odds-Ratio (aOR) 2.8 [95CI 1.6 to 4.8]), absolute lymphocyte count &lt;1G/L (aOR 3.0 [95CI 1.7 to 5.0]), systemic immunosuppressive treatments within 3 months of vaccination (aOR 4.5 [95CI 2.7 to 7.5]), together with the use of rituximab within 6 months (aOR 15.1 [95CI 4.3 to 52.7]). In a subsequent multivariate analysis conducted a subset of 227 patients (170 with detectable antibodies) with available gammaglobulinemia as well as B and T lymphocytes counts, factors remaining associated with the absence of antibody response were only low B-lymphocytes count (aOR 5.5 [95CI 2.4 to 12.3]) and time-interval from HSCT &lt; 12 months (aOR 3.3 [95CI 1.5 to 7.2]). CONCLUSION After 2 dose mRNA vaccination, the majority of allogeneic HSCT recipients developed an antibody response although a significant proportion of these responses may be insufficient. Studies are still needed to investigate the effect of a third vaccine dose in patients with a null or weak humoral response. Disclosures Loschi: Servier: Ended employment in the past 24 months, Honoraria; Novartis: Ended employment in the past 24 months, Honoraria; Gilead: Ended employment in the past 24 months, Honoraria; AbbVie: Ended employment in the past 24 months, Honoraria; CELGENE/BMS: Honoraria; MSD: Honoraria." @default.
• W3211551408 created "2021-11-22" @default.
• W3211551408 creator A5012400523 @default.
• W3211551408 creator A5012708136 @default.
• W3211551408 creator A5023091403 @default.
• W3211551408 creator A5027264417 @default.
• W3211551408 creator A5029106095 @default.
• W3211551408 creator A5036207495 @default.
• W3211551408 creator A5043268917 @default.
• W3211551408 creator A5049060278 @default.
• W3211551408 creator A5056848361 @default.
• W3211551408 creator A5065029786 @default.
• W3211551408 creator A5067800144 @default.
• W3211551408 creator A5078123316 @default.
• W3211551408 creator A5078618104 @default.
• W3211551408 creator A5080330335 @default.
• W3211551408 creator A5082128886 @default.
• W3211551408 creator A5085858552 @default.
• W3211551408 date "2021-11-05" @default.
• W3211551408 modified "2023-09-30" @default.
• W3211551408 title "Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients" @default.
• W3211551408 doi "https://doi.org/10.1182/blood-2021-149495" @default.
• W3211551408 hasPublicationYear "2021" @default.
• W3211551408 type Work @default.
• W3211551408 sameAs 3211551408 @default.
• W3211551408 citedByCount "2" @default.
• W3211551408 countsByYear W32115514082022 @default.
• W3211551408 crossrefType "journal-article" @default.
• W3211551408 hasAuthorship W3211551408A5012400523 @default.
• W3211551408 hasAuthorship W3211551408A5012708136 @default.
• W3211551408 hasAuthorship W3211551408A5023091403 @default.
• W3211551408 hasAuthorship W3211551408A5027264417 @default.
• W3211551408 hasAuthorship W3211551408A5029106095 @default.
• W3211551408 hasAuthorship W3211551408A5036207495 @default.
• W3211551408 hasAuthorship W3211551408A5043268917 @default.
• W3211551408 hasAuthorship W3211551408A5049060278 @default.
• W3211551408 hasAuthorship W3211551408A5056848361 @default.
• W3211551408 hasAuthorship W3211551408A5065029786 @default.
• W3211551408 hasAuthorship W3211551408A5067800144 @default.
• W3211551408 hasAuthorship W3211551408A5078123316 @default.
• W3211551408 hasAuthorship W3211551408A5078618104 @default.
• W3211551408 hasAuthorship W3211551408A5080330335 @default.
• W3211551408 hasAuthorship W3211551408A5082128886 @default.
• W3211551408 hasAuthorship W3211551408A5085858552 @default.
• W3211551408 hasBestOaLocation W32115514081 @default.
• W3211551408 hasConcept C126322002 @default.
• W3211551408 hasConcept C159654299 @default.
• W3211551408 hasConcept C203014093 @default.
• W3211551408 hasConcept C22070199 @default.
• W3211551408 hasConcept C2777408962 @default.
• W3211551408 hasConcept C2911091166 @default.
• W3211551408 hasConcept C3018913218 @default.
• W3211551408 hasConcept C45189115 @default.
• W3211551408 hasConcept C71924100 @default.
• W3211551408 hasConceptScore W3211551408C126322002 @default.
• W3211551408 hasConceptScore W3211551408C159654299 @default.
• W3211551408 hasConceptScore W3211551408C203014093 @default.
• W3211551408 hasConceptScore W3211551408C22070199 @default.
• W3211551408 hasConceptScore W3211551408C2777408962 @default.
• W3211551408 hasConceptScore W3211551408C2911091166 @default.
• W3211551408 hasConceptScore W3211551408C3018913218 @default.
• W3211551408 hasConceptScore W3211551408C45189115 @default.
• W3211551408 hasConceptScore W3211551408C71924100 @default.
• W3211551408 hasIssue "Supplement 1" @default.
• W3211551408 hasLocation W32115514081 @default.
• W3211551408 hasLocation W32115514082 @default.
• W3211551408 hasOpenAccess W3211551408 @default.
• W3211551408 hasPrimaryLocation W32115514081 @default.
• W3211551408 hasRelatedWork W191183980 @default.
• W3211551408 hasRelatedWork W1985560578 @default.
• W3211551408 hasRelatedWork W2024565325 @default.
• W3211551408 hasRelatedWork W2040659119 @default.
• W3211551408 hasRelatedWork W2095805334 @default.
• W3211551408 hasRelatedWork W2143955477 @default.
• W3211551408 hasRelatedWork W2416539388 @default.
• W3211551408 hasRelatedWork W2428175518 @default.
• W3211551408 hasRelatedWork W3183038350 @default.
• W3211551408 hasRelatedWork W3202220946 @default.
• W3211551408 hasVolume "138" @default.
• W3211551408 isParatext "false" @default.
• W3211551408 isRetracted "false" @default.
• W3211551408 magId "3211551408" @default.
• W3211551408 workType "article" @default.